Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Gross Margin (2017 - 2025)

Historic Gross Margin for Agios Pharmaceuticals (AGIO) over the last 8 years, with Q4 2025 value amounting to 90.59%.

  • Agios Pharmaceuticals' Gross Margin rose 23300.0% to 90.59% in Q4 2025 from the same period last year, while for Dec 2025 it was 88.26%, marking a year-over-year decrease of 3300.0%. This contributed to the annual value of 88.26% for FY2025, which is 3300.0% down from last year.
  • As of Q4 2025, Agios Pharmaceuticals' Gross Margin stood at 90.59%, which was up 23300.0% from 86.96% recorded in Q3 2025.
  • Agios Pharmaceuticals' Gross Margin's 5-year high stood at 92.34% during Q1 2024, with a 5-year trough of 59.25% in Q1 2022.
  • Moreover, its 4-year median value for Gross Margin was 89.19% (2023), whereas its average is 86.87%.
  • Data for Agios Pharmaceuticals' Gross Margin shows a peak YoY increase of 308700bps (in 2023) and a maximum YoY decrease of -87100bps (in 2023) over the last 5 years.
  • Over the past 4 years, Agios Pharmaceuticals' Gross Margin (Quarter) stood at 90.42% in 2022, then rose by 1bps to 91.75% in 2023, then fell by -4bps to 88.26% in 2024, then grew by 3bps to 90.59% in 2025.
  • Its last three reported values are 90.59% in Q4 2025, 86.96% for Q3 2025, and 86.33% during Q2 2025.